Detalhe da pesquisa
1.
Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures.
Blood
; 141(19): 2359-2371, 2023 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36626250
2.
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Lancet Oncol
; 24(7): 811-822, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414012
3.
Diagnosis and Management of Multiple Myeloma: A Review.
JAMA
; 327(5): 464-477, 2022 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35103762
4.
T Cell Repertoire Evolution after Allogeneic Bone Marrow Transplantation: An Organizational Perspective.
Biol Blood Marrow Transplant
; 25(5): 868-882, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30677510
5.
Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma.
Cancer Immunol Immunother
; 68(12): 1979-1993, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31686124
6.
Mixed 4f population of Tm adatoms on insulating Cu2N islands.
Phys Chem Chem Phys
; 22(1): 196-202, 2019 Dec 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-31799518
7.
Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
Biol Blood Marrow Transplant
; 24(7): 1386-1391, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29481870
8.
Individualized dynamic risk assessment for multiple myeloma.
medRxiv
; 2024 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38633807
9.
Emerging Strategies for the Prevention of Immune Toxicities Associated with T cell-Engaging Cancer Therapies.
Blood Cancer Discov
; 5(2): 90-94, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38175152
10.
Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma.
J Immunother Cancer
; 12(4)2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38609316
11.
Treatment Access for Gastrointestinal Stromal Tumor in Predominantly Low- and Middle-Income Countries.
JAMA Netw Open
; 7(4): e244898, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38568688
12.
Long-term Remissions Following CD20-directed Chimeric Antigen Receptor Adoptive T cell Therapy.
Blood Cancer Discov
; 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38747505
13.
The signature of a T-cell response to KSHV persists across space and time in individuals with epidemic and endemic KS from Uganda.
bioRxiv
; 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38370623
14.
The genomic landscape of Vk*MYC myeloma highlights shared pathways of transformation between mice and humans.
Nat Commun
; 15(1): 3844, 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38714690
15.
Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myeloma.
medRxiv
; 2023 Dec 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38106151
16.
Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL.
Blood Adv
; 7(5): 687-696, 2023 03 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36385536
17.
The Vk*MYC Mouse Model recapitulates human multiple myeloma evolution and genomic diversity.
bioRxiv
; 2023 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37546905
18.
Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma.
Nat Commun
; 14(1): 5335, 2023 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37660077
19.
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens.
Nat Cancer
; 4(12): 1660-1674, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37945755
20.
Serial Analysis of the T-Cell Receptor ß-Chain Repertoire in People Living With HIV Reveals Incomplete Recovery After Long-Term Antiretroviral Therapy.
Front Immunol
; 13: 879190, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35585986